Summary & Overview
HCPCS J3396: Verteporfin Injection, 0.1 mg
HCPCS Level II code J3396 denotes the injectable ophthalmic drug verteporfin at a unit of 0.1 mg, used primarily in photodynamic therapy for retinal conditions. Nationally, accurate coding of high-cost specialty injectables like verteporfin affects coverage determination, prior authorization workflows, and outpatient drug reimbursement. Clear identification of the HCPCS code supports consistent billing across ambulatory surgical centers, hospital outpatient departments, and ophthalmology clinics.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines how payers typically approach coverage for physician-administered ophthalmic injectables, common billing practices for unit reporting, and coding considerations relevant to facility and professional claims. Readers will find benchmarks on code usage and reimbursement patterns (where available), summaries of relevant payer policy themes such as prior authorization and medical necessity, and clinical context describing the service type and typical sites of service.
This summary presents a national perspective on coding and administrative implications for J3396, supporting revenue cycle, compliance, and clinical staff in applying the correct HCPCS Level II code for verteporfin injections.
Billing Code Overview
HCPCS Level II code J3396 represents an injection of verteporfin, packaged as 0.1 mg per billing unit. This code is used to report administration of the drug verteporfin, a photosensitizing agent commonly used in ophthalmology for procedures such as photodynamic therapy.
Service Type: Drug administration (injectable ophthalmic therapeutic)
Typical Site of Service: Ambulatory surgical center or hospital outpatient department, and other outpatient ophthalmology settings where photodynamic therapy is performed.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with choroidal neovascularization secondary to age-related macular degeneration (AMD) or other macular disorders who presents to an ophthalmology clinic or ambulatory surgery center for photodynamic therapy using verteporfin. The patient undergoes ophthalmic examination including visual acuity, slit-lamp exam, dilated fundus evaluation, and optical coherence tomography (OCT). If angiographic or OCT findings confirm a lesion amenable to verteporfin therapy, the medication J3396 (injection, verteporfin, 0.1 mg) is prepared and administered via intravenous infusion over approximately 10 minutes, followed by activation with a nonthermal diode laser at the lesion site per protocol. Vital signs and any infusion reactions are monitored during and after administration. Typical workflow steps include informed consent, preprocedure documentation, intravenous access placement, medication preparation and verification, administration with time-stamped infusion record, post-treatment observation for adverse effects, and documentation of the laser activation parameters and clinical response. Services are commonly provided in outpatient ophthalmology clinics, ambulatory surgery centers, or hospital outpatient departments where ophthalmic laser treatment is performed.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Normal billing for the service | Use when the service is the usual, standard service furnished by the provider. |